The EPS projection of ImmunoGen, Inc. (NASDAQ:IMGN) for quarter ended 2016-09-30 is $-0.4. A week before, the EPS forecast was $-0.4 against target of $-0.4, a month earlier. This estimate stood at $-0.4 60 days earlier versus forecast of $-0.4 90 days earlier, confirming a deviation of 0%.
ImmunoGen, Inc. (NASDAQ:IMGN) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 0.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 0, 0 and 0, respectively.
The downgrade of EPS estimates for ImmunoGen, Inc. (NASDAQ:IMGN) in the preceding 120, 60, 30 and 90 days were 0, 0, 0 and 0, in that order.
As per the latest update, for the quarter closed 3, the EPS estimate of ImmunoGen, Inc. (NASDAQ:IMGN) was $-0.4. This projection was computed after accounting 5 calls. As reported on 2016-04-29 the EPS was $-0.37. The change was $-0.07, demonstrating a percentage deviation of -23.33%. The projections confirmed a standard deviation of 0.04.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for ImmunoGen, Inc. (NASDAQ:IMGN) stands at $16.86 and the median estimate at $16.68. Almost 3 analysts announced their estimates.
The highest estimate is $17.8 while the lowest target is $16.1 showing standard deviation of 0.864%.
As many as 3 analysts released sales estimates reised in upside while 3 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 3 revised sales number projection on upside while 3 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 3 hiked sales estimations and 3 reduced sales forecast. ImmunoGen, Inc. (NASDAQ:IMGN) stated that the change in forecast was -11.127%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...